Form 4: Senti Biosciences CFO John Harry Cross III Acquires Stock Options

John Harry Cross III, CFO of Senti Biosciences, acquired stock options for 174,200 shares at an exercise price of $3.52 on March 7, 2025.

Summary

• On March 7, 2025, John Harry Cross III, the Chief Financial Officer of Senti Biosciences, Inc. (SNTI), acquired stock options.
• The stock options grant the right to buy 174,200 shares of Senti Biosciences common stock at an exercise price of $3.52 per share.
• These options vest over time, with 25% vesting on March 3, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• The vesting is contingent upon Mr. Cross's continued service with the company.
• The options expire on March 6, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock options, which is generally viewed as a positive sign of aligning management incentives with shareholder value. It's a neutral event with a slightly positive undertone.

Positives

• The acquisition of stock options by the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 25% after one year and the remainder over the following three years is a typical vesting arrangement.
• Comparable companies such as CRISPR Therapeutics, Beam Therapeutics, and Editas Medicine also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the CFO's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the company to its leadership.

Key Dates